Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04707768 · ClinicalTrials.gov registry record · Phase 3
Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects
A Phase 3 study, sponsored by Akebia Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 456
- Enrollment target
NCT04707768 is a Phase 3 study that has completed, run by Akebia Therapeutics. The registered enrollment target is 456 participants.
The verdict
NCT04707768, a Phase 3 study, has completed, sponsored by Akebia Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 456 participants
- Enrollment target
Study Summary
This study will be conducted to demonstrate the efficacy and safety of vadadustat administered three times weekly (TIW) compared to a long-acting erythropoiesis-stimulating agent (ESA) (Mircera®) for the maintenance treatment of anemia in hemodialysis participants.
Interventions
- DRUG Vadadustat
- DRUG Mircera®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 456 participants |
| Start Date | 2021-06-18 |
| Est. Completion | 2023-01-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04707768
The ClinicalTrials.gov registry entry for NCT04707768 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 456 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Akebia Therapeutics, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vadadustat is the first listed.
NCT04707768 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04707768 about?
NCT04707768 is a clinical study titled "Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects". This study will be conducted to demonstrate the efficacy and safety of vadadustat administered three times weekly (TIW) compared to a long-acting erythropoiesis-stimulating agent (ESA) (Mircera®) for the maintenance treatment of anemia in hemodialysis participants.
What is the current status of trial NCT04707768?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 456 participants. The study started on 2021-06-18. Estimated completion is 2023-01-30.
What interventions are being tested in trial NCT04707768?
The interventions under investigation include: Vadadustat (DRUG), Mircera® (DRUG).
Who is sponsoring clinical trial NCT04707768?
This trial is sponsored by Akebia Therapeutics, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.